2022 World Conference on Lung Cancer (ePosters)-EP08.02-016. Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs

EP08.02-016. Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs

Back to course

Pdf Summary

A study examined real-world treatment patterns, outcomes, healthcare resource utilization (HRU), and costs in frontline and post-osimertinib settings for patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC). The study analyzed data from a large US administrative health claims database, including 70 million patients. The study population consisted of insured adults with a lung cancer diagnosis between January 1, 2008, and March 31, 2021, who had evidence of EGFR testing or received an EGFR tyrosine kinase inhibitor. <br /><br />The analysis compared three cohorts: frontline, post-osimertinib, and post-osimertinib/platinum chemotherapy. The study found that compared to the FLAURA clinical trial and the AURA3 clinical trial, real-world overall survival (OS) among patients with EGFR-mutated advanced NSCLC was lower at 21 months and 9 months, respectively. Patients who progressed on osimertinib had poor outcomes, higher HRU, and higher costs compared to patients on frontline treatment. <br /><br />The study revealed that in the frontline cohort, patients who received osimertinib had longer median time to treatment discontinuation, time to next treatment, and overall survival compared to those who received another frontline therapy. Patients who progressed on osimertinib had higher HRU and costs, primarily driven by pharmacy costs, compared to those on frontline treatment. <br /><br />The results highlight the need for innovative and effective therapies for patients who progress on osimertinib and demonstrate the existence of unmet needs in the frontline treatment of EGFR-mutant advanced NSCLC. It is important to note that the real-world study population may differ from patients enrolled in clinical trials, potentially impacting outcomes. The study was funded by Janssen Research & Development, LLC, and medical writing and editorial support were provided by Janssen Global Services, LLC.

Asset Subtitle

Benjamin Besse

Meta Tag

Speaker Benjamin Besse

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

real-world treatment patterns

outcomes

healthcare resource utilization

costs

frontline setting

post-osimertinib setting

EGFR-mutant advanced non-small cell lung cancer

administrative health claims database

FLAURA clinical trial

AURA3 clinical trial